<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367106">
  <stage>Registered</stage>
  <submitdate>16/09/2014</submitdate>
  <approvaldate>7/10/2014</approvaldate>
  <actrnumber>ACTRN12614001073695</actrnumber>
  <trial_identification>
    <studytitle>A Multi-centre, Observational Study of Patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network</studytitle>
    <scientifictitle>A Multi-centre, Observational Study by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network To Determine The Clinical Characteristics, Laboratory Features, Treatments, and Clinical Outcomes in Patients with Microangiopathic Thrombocytopenia
</scientifictitle>
    <utrn>U1111-1161-8119 </utrn>
    <trialacronym>APMAT 1</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Microangiopathic Thrombocytopenia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is an observational study of previously diagnosed and treated microangiopathic thrombocytopenia (MAT) patients. MAT is a rare collection of disorders caused by the formation of intravascular aggregates of platelets resulting in microcirculatory thrombosis, red blood cell destruction and vital end-organ damage. The study will collect clinical and laboratory data to assess the disease characteristics, laboratory features, treatment strategies employed, and clinical outcome. Each participant will be observed for 6 months once they are enrolled in the study.</interventions>
    <comparator>Not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the clinical characteristics of microangiopathic thrombocytopenia including symptoms, potential precipitating factors, outcome, genetic, autoantibody and immune complex factors. Data will be collected by reviewing patients' medical records.</outcome>
      <timepoint>Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the treatments given for microangiopathic thrombocytopenia. Data will be collected by reviewing patients' medical records.</outcome>
      <timepoint>Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine laboratory features microangiopathic thrombocytopenia patients. Methods for analysis include standard coagulation tests and cell counts, flow cytometry, immunoassays, activity assays and/or genotyping. </outcome>
      <timepoint>Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the value of ADAMTS13 testing in predicting disease relapse. Immunoassays and activity assays will be performed on blood samples collected at enrolment and six months post-enrolment.</outcome>
      <timepoint>Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the value of ADAMTS13 genetic mutations in predicting disease relapse. Genotyping will be performed on blood samples collected at enrolment and six months post-enrolment.</outcome>
      <timepoint>Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To establish a MAT Biobank for further testing of novel assays used for the diagnosis and scientific understanding of MAT.</outcome>
      <timepoint>18 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To facilitate basic disease mechanism and translational clinical research.</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients presenting to a study centre and diagnosed with microangiopathic thrombocytopenia as defined by but not limited to anaemia, thrombocytopenia (&lt;150 x10^9/L) and evidence of fragmented red blood cells (schistocytes) on blood film.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who have non-microangiopathic thrombocytopenia and/or thrombosis where an alternate diagnosis is likely.

Patients who are unable or unwilling to provide informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>The sample size of this study (200) was selected to provide an observational overview of MAT patients in the APMAT Network. Interpretation of the data will be descriptive and no comparative interpretation of the data will be made. Where applicable, descriptive statistics in the form of mean (+/-SD), median and range for continuous variables and proportions (%) for categorical variables will be conducted.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>True</patientregistry>
    <followup>6</followup>
    <followuptype>Months</followuptype>
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>22/09/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>31/12/2019</anticipatedenddate>
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA,VIC</recruitmentstate>
    <hospital>The Alfred - Prahran </hospital>
    <hospital>Calvary Mater Newcastle - Waratah</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <hospital>Royal Melbourne Hospital - City campus - Parkville</hospital>
    <hospital>St Vincent's Private Hospital (Darlinghurst) - Darlinghurst</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Hollywood Private Hospital - Nedlands</hospital>
    <countryoutsideaustralia>
      <country>China</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan, Province Of China</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic Of</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>ASTH</primarysponsorname>
    <primarysponsoraddress>c/o PO Box 217
Glen Iris
Victoria 3146
</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Australasian Society of Thrombosis and Haemostasis (ASTH)</fundingname>
      <fundingaddress>c/o PO Box 217
Glen Iris
Victoria 3146
</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Alexion Pharmaceuticals Australasia Pty Limited</fundingname>
      <fundingaddress>Suites 226-227
117 Old Pittwater Road
Brookvale
NSW  2100</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>BAXALTA US INC.</fundingname>
      <fundingaddress>120 Lakeside Dr
Bannockburn
IL 60015, USA </fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Asia-Pacific Society on Thrombosis and Haemostasis (APSTH)</sponsorname>
      <sponsoraddress>c/o PO Box 217
Glen Iris
Victoria 3146
</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an observational study of patients who have previously been diagnosed and treated for Microangiopathic Thrombocytopenia (MAT). The study will collect clinical and laboratory data to assess the disease characteristics, laboratory features, treatments, and clinical outcome. </summary>
    <trialwebsite>www.aptin.org</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hollywood Private Hospital Research Ethics Committee</ethicname>
      <ethicaddress>Hollywood Private Hospital
Monash Avenue
Nedlands
WA 6009</ethicaddress>
      <ethicapprovaldate>14/08/2014</ethicapprovaldate>
      <hrec>HPH383</hrec>
      <ethicsubmitdate>13/05/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>NEAF: Hunter New England Human Research Ethics Committee </ethicname>
      <ethicaddress>Hunter New England Research Support and Development Office
Locked Bag No.1
New Lambton NSW 2305</ethicaddress>
      <ethicapprovaldate>25/02/2016</ethicapprovaldate>
      <hrec>15/07/15/3.03</hrec>
      <ethicsubmitdate>17/07/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committees</ethicname>
      <ethicaddress>Ministry of Health
Freyberg Building
20 Aitken Street
PO Box 5013
Wellington 6011</ethicaddress>
      <ethicapprovaldate>8/05/2015</ethicapprovaldate>
      <hrec>15/NTA/25</hrec>
      <ethicsubmitdate>26/02/2015</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Ross Baker</name>
      <address>Perth Blood Institute, 
Hollywood Specialist Centre
3/95 Monash Avenue
Nedlands
WA 6009</address>
      <phone>+61 892004904</phone>
      <fax />
      <email>ross@aptin.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jim Tiao</name>
      <address>Perth Blood Institute, 
Hollywood Specialist Centre
3/95 Monash Avenue
Nedlands
WA 6009</address>
      <phone>+61 93601319</phone>
      <fax />
      <email>jim@aptin.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Ross Baker</name>
      <address>Perth Blood Institute, 
Hollywood Specialist Centre
3/95 Monash Avenue
Nedlands
WA 6009</address>
      <phone>+61 892004904</phone>
      <fax />
      <email>ross@aptin.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Giuliana D'Aulerio</name>
      <address>Perth Blood Institute, 
Hollywood Specialist Centre
3/95 Monash Avenue
Nedlands
WA 6009</address>
      <phone>+61 892004904</phone>
      <fax />
      <email>giuliana@aptin.org</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>